Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC With Donafenib for Adjuvant Treatment of HCC After Hepatectomy
NCT04962958Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Recurrence-Free Survival at 2 years. Started Dec 2021; status: completed.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04962958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962958.